Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swedish (OMX) Healthcare Sector Analysis

UpdatedMar 02, 2026
DataAggregated Company Financials
Companies153
  • 7D0.5%
  • 3M-5.9%
  • 1Y-7.7%
  • YTD-2.7%

Over the last 7 days, the Healthcare industry has remained flat, although notably Sectra gained 7.8%. Unfortunately though, the industry is down 7.7% over the past 12 months. Earnings are forecast to grow by 24% annually.

Sector Valuation and Performance

Has the Swedish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Mon, 02 Mar 2026SEK 567.7bSEK 229.0b-SEK 2,378,234,487.1432.1x-238.7x2.5x
Wed, 28 Jan 2026SEK 603.4bSEK 257.4bSEK 4.8b39.5x124.4x2.3x
Fri, 26 Dec 2025SEK 583.9bSEK 230.5bSEK 3.6b43.6x160.1x2.5x
Sun, 23 Nov 2025SEK 583.3bSEK 230.8bSEK 3.3b44.3x178.7x2.5x
Tue, 21 Oct 2025SEK 600.5bSEK 228.0bSEK 2.3b42.8x257.3x2.6x
Thu, 18 Sep 2025SEK 607.1bSEK 227.2bSEK 6.6b45.3x92x2.7x
Sat, 16 Aug 2025SEK 609.0bSEK 226.8bSEK 6.6b46.3x92.3x2.7x
Mon, 14 Jul 2025SEK 630.8bSEK 226.6bSEK 6.0b44.8x104.7x2.8x
Wed, 11 Jun 2025SEK 624.8bSEK 226.4bSEK 5.8b43.1x107.4x2.8x
Fri, 09 May 2025SEK 594.8bSEK 223.9bSEK 4.9b37.4x120.6x2.7x
Sun, 06 Apr 2025SEK 537.6bSEK 221.5bSEK 5.4b32.5x99.5x2.4x
Tue, 04 Mar 2025SEK 587.3bSEK 206.3bSEK 4.6b35.7x128.9x2.8x
Thu, 30 Jan 2025SEK 599.9bSEK 203.9b-SEK 2,760,695,493.5341.5x-217.3x2.9x
Sat, 28 Dec 2024SEK 584.7bSEK 202.6b-SEK 2,502,952,636.9339x-233.6x2.9x
Mon, 25 Nov 2024SEK 506.5bSEK 199.8b-SEK 2,629,608,983.7436.2x-192.6x2.5x
Wed, 23 Oct 2024SEK 588.7bSEK 198.8b-SEK 3,271,139,618.2141.2x-180x3x
Fri, 20 Sep 2024SEK 617.0bSEK 200.1b-SEK 2,821,459,736.3140.3x-218.7x3.1x
Sun, 18 Aug 2024SEK 598.9bSEK 200.2b-SEK 2,426,924,273.8440.9x-246.8x3x
Tue, 16 Jul 2024SEK 578.2bSEK 196.4b-SEK 3,104,909,178.6440x-186.2x2.9x
Thu, 13 Jun 2024SEK 557.3bSEK 195.4b-SEK 3,081,138,185.3636x-180.9x2.9x
Sat, 11 May 2024SEK 549.1bSEK 196.7b-SEK 2,692,444,446.9636.5x-203.9x2.8x
Mon, 08 Apr 2024SEK 523.8bSEK 192.8b-SEK 3,173,203,059.4345.6x-165.1x2.7x
Wed, 06 Mar 2024SEK 505.8bSEK 192.2b-SEK 3,657,816,455.3144.9x-138.3x2.6x
Fri, 02 Feb 2024SEK 647.0bSEK 193.3b-SEK 613,777,298.0047.8x-1054.1x3.3x
Sun, 31 Dec 2023SEK 541.1bSEK 191.2b-SEK 963,424,829.0048.2x-561.7x2.8x
Tue, 28 Nov 2023SEK 498.8bSEK 190.0b-SEK 1,220,964,888.0049.5x-408.5x2.6x
Thu, 26 Oct 2023SEK 429.7bSEK 187.4b-SEK 1,716,997,547.0030.9x-250.3x2.3x
Sat, 23 Sep 2023SEK 460.1bSEK 185.6b-SEK 2,027,518,382.0036.3x-226.9x2.5x
Mon, 21 Aug 2023SEK 457.5bSEK 185.0b-SEK 1,098,701,796.0039.5x-416.4x2.5x
Wed, 19 Jul 2023SEK 472.7bSEK 179.8b-SEK 1,543,622,137.0045.6x-306.2x2.6x
Fri, 16 Jun 2023SEK 522.4bSEK 178.9b-SEK 773,022,049.0046.4x-675.8x2.9x
Sun, 14 May 2023SEK 518.1bSEK 176.8b-SEK 880,193,524.0042.2x-588.6x2.9x
Tue, 11 Apr 2023SEK 504.0bSEK 172.7b-SEK 1,424,912,715.0035.7x-353.7x2.9x
Thu, 09 Mar 2023SEK 487.7bSEK 172.1b-SEK 1,368,578,404.0037.4x-356.4x2.8x
Price to Earnings Ratio

-356.4x


Total Market Cap: SEK 487.7bTotal Earnings: -SEK 1,368,578,404.00Total Revenue: SEK 172.1bTotal Market Cap vs Earnings and Revenue0%0%0%
Swedish Healthcare Sector Price to Earnings3Y Average -168.5x202420252026
Current Industry PE
  • Investors are relatively neutral on the Swedish Healthcare industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PS ratio of 2.7x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have deteriorated over the last three years.
  • Meanwhile revenues for these companies have grown 10.0% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has caused losses to expand.

Industry Trends

Which industries have driven the changes within the Swedish Healthcare sector?

SE Market1.88%
Healthcare0.51%
Healthtech7.27%
Life Sciences6.10%
Medical Equipment1.73%
Healthcare Services1.53%
Pharma-0.098%
Biotech-2.40%
Industry PE
  • Investors are most optimistic about the Healthtech industry, which is trading close to its 3-year average PE ratio of 115x.
    • Analysts are expecting annual earnings growth of 16.5%, which is lower than the prior year's growth of 40.0% per year.
Forecasted Growth
  • Analysts are most optimistic on the Pharma industry, expecting annual earnings growth of 34% over the next 5 years.
  • This is better than its past earnings growth rate of 14% per year.
  • In contrast, the Healthtech industry is expected to see its earnings grow by 16% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
SECT B SectraSEK 193.307.6%
+SEK 2.6b		-19.2%PE57.6x
BONEX Bonesupport HoldingSEK 197.709.3%
+SEK 1.3b		-48.1%PE92.9x
EKTA B ElektaSEK 56.953.8%
+SEK 802.4m		-4.5%PE74.5x
ALIF B AddLifeSEK 149.504.0%
+SEK 706.8m		-8.2%PE32.5x
MCOV B MedicoverSEK 217.501.4%
+SEK 452.9m		2.4%PE39.6x

Latest News

BINV
SEK 22.15
BioInvent International
7D
-16.1%
1Y
-17.4%
SANION
SEK 16.16
Saniona
7D
-32.1%
1Y
139.4%
BONEX
SEK 197.70
Bonesupport Holding
7D
9.3%
1Y
-48.1%
SOBI
SEK 388.60
Swedish Orphan Biovitrum
7D
-5.2%
1Y
21.1%
AMBEA
SEK 129.10
Ambea
7D
3.6%
1Y
18.3%

AMBEA: Acquisition Pipeline And Higher Dividend Will Support Future Expansion

Analysts have trimmed their price target on Ambea to SEK158 from about SEK162, reflecting updated views on fair value, a slightly higher discount rate and more cautious assumptions around revenue growth and profit margins, while keeping a broadly similar future P/E outlook. What's in the News Ambea is actively looking for acquisitions across its markets, with management highlighting a focus on quality targets with solid operational performance and an active pipeline in all countries and business areas except Klara (Key Developments).
VITR
SEK 92.35
Vitrolife
7D
2.7%
1Y
-52.5%

VITR: Genetic Services Restructuring And Impairment Will Support Future Upside Potential

Analysts have left their SEK 176.75 price target for Vitrolife unchanged, with only minimal tweaks to inputs such as discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News Vitrolife plans to record a goodwill impairment of SEK 5.4b in the fourth quarter of 2025, linked to the Igenomix acquisition (company announcement).
IMP A SDB
SEK 44.25
Implantica
7D
-8.1%
1Y
29.2%
EKTA B
SEK 56.95
Elekta
7D
3.8%
1Y
-4.5%
BIOA B
SEK 302.40
BioArctic
7D
-7.6%
1Y
35.6%
ASKER
SEK 61.73
Asker Healthcare Group
7D
-3.5%
1Y
n/a
MCOV B
SEK 217.50
Medicover
7D
1.4%
1Y
2.4%

MCOV B: Higher Margin Outlook And Dividend Plans Will Support Future Upside

Analysts have nudged their Medicover price target higher to SEK257.29 from SEK252.68, citing updated assumptions that pair slightly lower revenue growth expectations with a modestly stronger profit margin and a revised future P/E of 24.46x. What's in the News Board proposes a dividend of €0.20 per share for the 2025 financial year, compared with €0.15 previously, subject to approval at the annual general meeting on 29 April 2026 (Key Developments).
CAMX
SEK 484.80
Camurus
7D
-4.5%
1Y
-27.8%
SECT B
SEK 193.30
Sectra
7D
7.6%
1Y
-19.2%

SECT B: Expanding Cloud Imaging Footprint Will Drive Future Upside Potential

Analysts have maintained their SEK 245.0 price target for Sectra with only minor adjustments to assumptions, including a slightly higher discount rate and a marginally different future P/E. This reflects a largely steady view of the company’s valuation drivers.
VIMIAN
SEK 25.74
Vimian Group
7D
-3.0%
1Y
-34.8%

VIMIAN: Reset Expectations Will Highlight Execution Under New CEO Appointment

Analysts have trimmed their fair value estimate and price target on Vimian Group to SEK 27 from SEK 37, reflecting updated assumptions around slightly higher growth, a lower profit margin profile and a higher expected P/E multiple, which together point to a more cautious risk return trade off. Analyst Commentary Bullish analysts looking at Vimian Group are focusing less on the headline downgrade and more on what the revised SEK 27 target implies for execution, valuation and growth expectations from here.
MCAP
SEK 485.00
MedCap
7D
4.4%
1Y
26.5%
ALIF B
SEK 149.50
AddLife
7D
4.0%
1Y
-8.2%

Investors Shouldn't Be Too Comfortable With AddLife's (STO:ALIF B) Earnings

Feb 12
Investors Shouldn't Be Too Comfortable With AddLife's (STO:ALIF B) Earnings